Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiomyopeptidin in STEMI Patients Undergoing Direct PCI
NCT03958422Phase 4Unknown
- Sponsor
- Zhen-Ao Bio-Tech
- Start
- Jun 2019
- Primary completion
- Nov 2019
- Modality
- Peptides
01
Overview
Phase 4, randomised, single-blind trial of cardiomyopeptidin in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Zhen-Ao Bio-Tech. Primary endpoint: Myocardial infarct size at 7 days. Status: unknown.
02
Drugs
cardiomyopeptidin
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03958422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03958422.